Lupin Regulatory Approval

Lupin Business Update

Lupin Limited disclosed that the U.S. FDA concluded an inspection at its Goa manufacturing facility, closing with a Form-483 containing one observation. The company will respond within the stipulated timeframe.

Lupin Management Change

Lupin Limited appointed Mr. Brian Savage as President and Chief Legal Officer, effective October 22, 2026. He will oversee global legal, compliance, and IP functions.

Lupin Employee Stock Options

Lupin Limited has granted 40,157 stock options to employees under its existing ESOP scheme at an exercise price of ₹2.00 per share.

Lupin Board Meeting Date

Lupin Limited scheduled a Board meeting on November 03, 2026, to consider and approve its unaudited standalone and consolidated financial results.

Lupin Other Announcement

Lupin Limited received an ESG rating of 70 for FY26 from NSE Sustainability Ratings and Analytics. The assessment was independently prepared using publicly available information.

Lupin Regulatory Approval

Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion, USP (1 mg/0.5 mL single-dose prefilled syringe).

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.